NECTIN3-AS1: A Potential Drug Target and Biomarker (G100506555)

Target Name: NECTIN3-AS1

NCBI ID: G100506555

NECTIN3-AS1

Other Name(s): PVRL3-AS1 | NECTIN3 antisense RNA 1

NECTIN3-AS1: A Potential Drug Target and Biomarker

Nectin3-AS1, also known as NEC3-AS1, is a protein that is expressed in various tissues, including the brain, heart, and gastrointestinal tract. It is a member of the Nectin family, which is characterized by the presence of a nucleotide-binding oligomerization domain (NBD) and a conserved C-end region. The NEC3-AS1 gene has not yet been fully characterized, but its function and potential as a drug target or biomarker is under investigation.

The NEC3-AS1 protein is involved in several cellular processes, including cell adhesion, migration, and invasion. It is a critical regulator of the actin-associated protein 2 (Alp) complex, which is involved in the formation of actin filaments and in the regulation of cell growth and differentiation. The Alp complex is a protein that is composed of two subunits, alpha-actinin and alpha-tubulin, and it is composed of several non-protein subunits, including NEC3-AS1.

NEC3-AS1 has been shown to play a role in the regulation of cell migration and the establishment of tissue structures. For example, studies have shown that NEC3-AS1 is involved in the regulation of the migration of cancer cells through the endoplasmic reticulum (ER) and the blood-brain barrier (BBB). It has also been shown to be involved in the regulation of cell adhesion and the formation of tight junctions, which are important for the barrier function of epithelial cells.

In addition to its role in cell biology, NEC3-AS1 is also being investigated as a potential drug target or biomarker. The NEC3-AS1 protein has been shown to be highly conserved across different species, which suggests that it may be a good candidate for targeting with small molecules or antibodies. Several studies have shown that NEC3-AS1 is involved in several cellular processes that are important for the development and progression of cancer, including cell growth, apoptosis, and angiogenesis.

One potential mechanism by which NEC3-AS1 may be targeted with drugs is through its role in the regulation of cell adhesion. Many drugs that are used to treat cancer, such as those that target cell-surface receptors or intracellular signaling pathways, act by modulating the strength and structure of cell-cell adhesion. NEC3-AS1 is involved in the regulation of cell adhesion through its role in the Alp complex, and it is possible that drugs that target NEC3-AS1 may be effective in treating some types of cancer.

Another potential mechanism by which NEC3-AS1 may be targeted with drugs is through its role in the regulation of cell migration. Many drugs that are used to treat cancer, such as those that target the Philadelphia-derived kinase (PDK) signaling pathway, act by modulating the movement of cells. NEC3-AS1 is involved in the regulation of cell migration through its role in the Alp complex, and it is possible that drugs that target NEC3-AS1 may be effective in treating some types of cancer.

In addition to its potential as a drug target or biomarker, NEC3-AS1 is also being investigated for its potential as a diagnostic biomarker. The NEC3-AS1 protein is expressed in several tissues and has been shown to be involved in several cellular processes that are important for the development and progression of cancer. It is possible that NEC3-AS1 may be a useful biomarker for the diagnosis and prognosis of some types of cancer.

Overall, NEC3-AS1 is a protein that is involved in several cellular processes that are important for the development and progression of cancer. Its role in the regulation of cell adhesion, migration, and

Protein Name: NECTIN3 Antisense RNA 1

The "NECTIN3-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NECTIN3-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets